Citations

Clear

60 citation(s) found for "Scharf, E".

White Matter Hyperintensity Association With Cognitive Impairment and Mortality in a Population-Based Cohort of Incident Parkinsonism
Malfer, Lorenzo , Mullan, Aidan F. , Camerucci, Emanuele, Turcano, Pierpaolo , Giorgi, Andrea, Yu, Jinna , Huston, John , Scharf, Eugene , Brown, Robert D. , Bower, James H. , Savica, Rodolfo , Huston, John , Scharf, Eugene L , Brown, Robert D , Mullan, Aidan , Camerucci, Emanuele , Yu, Jinna

Mayo Clinic

Neurology Open Access | August 18, 2026 | Volume: 2 | Issue: 3 | Pages: No page available

10.1212/wn9.0000000000000151 Get It

An Assessment of Time Toxicity in Patients Receiving [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Scharf, Zachary, Muniz, Miguel, Tchitchkan, Elizabeth , Rami, Avina , Ravi, Praful , Orme, Jacob J., Tarhini, Ali, Jacene, Heather A. , Sentana‐Lledo, Daniel , Scharf, Zachary , Muniz, Miguel , Orme, Jacob J , Tarhini, Ali , Childs, Daniel S , Rami, Avina , Orme, Jacob J. , Childs, Daniel S.

Mayo Clinic

The Oncologist | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/oncolo/oyag327 | PMID 42606561 Get It

Abstract BACKGROUND [177Lu]Lu-PSMA-617 improves survival and quality of life in men with metastatic castration-resistant prostate cancer but requires substantial healthcare involvement. Our analysis evaluated the time toxicity associated with [177Lu]Lu-PSMA-617, representing the first dedicated radioligand time toxicity assessment. MATERIALS AND METHODS We conducted a multi-institutional retrospective study of patients initiating [177Lu]Lu-PSMA-617 between April 2022 and March 2023. Patients were followed from first [177Lu]Lu-PSMA-617 administration until 3 months after the final cycle, initiation of new systemic therapy, or death. Time toxicity was quantified as healthcare contact days during the at-risk interval. Associations with baseline characteristics were evaluated using negative binomial regression models. Univariate and multivariable models were performed. RESULTS Among 135 patients, median age was 69 years and median prior systemic therapies was 4. Patients completed a median of 5 [177Lu]Lu-PSMA-617 cycles over 7.6 months. Median healthcare contact days were 20 (IQR, 15–28), representing 9.5% (IQR, 6.4–13.9) of at-risk days. Fifteen patients (11%) experienced high time toxicity (>1 contact day per 5 days), while 42 (31%) had low time toxicity (≤1 contact day per 14 days). Among the 57 patients who received both cycle 1 and cycle 6, mean per cycle healthcare contact days were 4 and 3.6, respectively (paired Wilcoxon signed-rank test, p = 0.04). Routine oncology visits comprised 32.7% of contact days, compared with 8.8% from hospitalizations. Lower baseline hemoglobin was independently associated with greater time toxicity (RR = 0.87; 95% CI, 0.79–0.96; p = 0.004). CONCLUSION In heavily pretreated patients, [177Lu]Lu-PSMA-617 demonstrated relatively low time toxicity, supporting it as a time-efficient therapy.
Silent cerebral infarction risk in a pathology proven papillary fibroelastoma cohort
Septar, H Memis, Aboukhatwa, O, Brown, R, Scharf, E, Akiki, E, Kurmann, R, Bois, M, Maleszewski, J, Klarich, K, Memis, Hayat, Aboukhatwa, Omar , Brown, R D, Scharf, Eugene , Akiki, Elias , Kurmann, Reto , Bois, Melanie C. , Maleszewski, Joseph J. , Klarich, Kyle W.

Mayo Clinic

European Heart Journal Supplements | August 3, 2026 | Volume: 28 | Issue: Supplement_8 | Pages: No page available

10.1093/eurheartjsupp/suag097.085 Get It

Abstract Background Cardiac papillary fibroelastoma (PFE) is the most common benign primary cardiac tumor. Despite their benign pathology, PFEs pose a significant embolic risk, which can lead to severe neurological sequelae. However, subclinical or silent emboli often go undetected, presenting a diagnostic challenge. This study aims to assess the prevalence of silent emboli in patients with pathology-proven PFEs using brain magnetic resonance imaging (MRI). Methods We conducted a retrospective review of 385 cases of pathology-confirmed PFEs. Inclusion criteria was those with brain MRI performed within 5 years of surgical resection of the PFE and no clinical neurological events. Patients with a history of symptomatic cerebral infarction (stroke or TIA) were excluded. Patient demographics and PFE imaging features were analyzed by two cardiologists experienced in cardiac tumors. Clinical neurological data, and MRI findings were analyzed by two neurologists with expertise in cerebrovascular disease. Results Out of 385 patients, 132 underwent brain MRI. In the entire cohort, 105/385 patients (27%) experienced clinically overt embolic events. After excluding patients with symptomatic cerebral infarctions and MRI scans older than 5 years, 27 patients (mean age: 71±9.6, gender: 66% female) met the inclusion criteria. Of these, 8 patients (30%) showed signs of silent infarctions on MRI, with 4 (15%) displaying findings consistent with cerebral infarction highly suggestive for embolic source. Conclusion This study underscores the substantial risk of silent cerebral embolic events in patients with PFE. The limited availability of MRI data, largely attributable to the absence of standardized neuroimaging protocols, indicates that the true prevalence of silent embolization in this population is likely underestimated. Given the propensity of PFE to generate clinically silent emboli, systematic cerebral MRI should be strongly considered as part of the diagnostic assessment of patients with cardiac masses, irrespective of neurological symptoms. Early identification of subclinical cerebrovascular lesions may facilitate timely therapeutic decision-making and secondary prevention strategies, thereby reducing the risk of future symptomatic and potentially disabling ischemic strokes.
Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease
Arlt, Friederike A. , Miske, Ramona , Appeltshauser, Luise , Zinnow, Viktoria , Borowski, Kathrin , Stenzel, Werner, Meisel, Andreas , Ruprecht, Klemens, Endres, Matthias , Blau, Igor, Kirchner, Marieluise , Mertins, Philipp , Sanchez-Sendin, Elisa, Wernick, Stephanie , Pressler, Hannah, Stascheit, Frauke , Linke, Janis, Hümmert, Sophie , Werner, Hauke B., Wibisono, Esravila Ariya , Doppler, Kathrin, Komorowski, Lars , Spiliotis, Elias T, Dubey, Divyanshu, Zeckeridou, Anastasia, Mills, John R, Scharf, Madeleine, Prüss, Harald, Werner, Hauke , Meisel, Andreas , Endres, Matthias , Stascheit, Frauke , Pittock, S J , McKeon, Andrew , Prüss, Harald , Arlt, Friederike Antonia , Stenzel, Werner , Radbruch, Helena , Ruprecht, Klemens, Sánchez-Sendín, Elisa , Preßler, Hannah , Linke, Janis , Doppler, Kathrin , Spiliotis, Elias T. , Dubey, Divyanshu , Ζεκερίδου, Αναστασία , Pittock, Sean J. , Mills, J R , McKeon, Andrew , Prüß, Harald

Mayo Clinic

Brain | May 29, 2026 | Volume: 149 | Issue: 8 | Pages: 2731-2746

10.1093/brain/awag183 | PMID 42252093 Get It

Abstract Severe neuropathies with predominant involvement of motor fibres can resemble lower motor neuron disease (LMND) phenotypes. Given the fatal prognosis of LMND, identifying underlying autoimmune syndromes is crucial to provide treatment options to patients. We investigated a novel autoantibody binding pattern observed on murine teased sciatic nerve fibres. Target antigens were identified using immunoprecipitation combined with mass spectrometry. Target specificity of these autoantibodies was validated in cell-based assays, neutralization assays and knock-out models. A retrospective study cohort consisting of different neuropathies (chronic inflammatory demyelinating polyradiculopathy n = 86, Guillain–Barré syndrome n = 37, multifocal motor neuropathy n = 18, diabetic neuropathy n = 30, other inflammatory neuropathies n = 10), amyotrophic lateral sclerosis (n = 50), multiple sclerosis (n = 50) and healthy controls (n = 50) was negative for septin multimer autoantibodies. Histopathological analysis of skin and the sural nerve including electron microscopy was performed in one seropositive patient, and autoantibody binding was characterized in vitro. Extensive immunotherapy was initiated in one patient, with clinical and serological follow-up over 4 years. Among 3543 total samples tested, three patients (two male, one female)—diagnosed with the LMND variant of amyotrophic lateral sclerosis (aged 65, 72 and 79 years, respectively)—showed a novel and distinct autoantibody binding pattern of indirect immunofluorescence staining on peripheral nerves, targeting Schmidt–Lanterman incisures (SLIs), paranodes and the abaxonal myelin. Target identification and validation revealed septin multimers as autoantibody epitopes. Despite the primarily intracellular location of septins, autoantibody binding was evident in living myelinated dorsal root ganglia, primarily at SLIs (‘incisuropathy’). Septin multimer autoantibodies further initiated complement deposition on fixed and permeabilized cell-based assays. Sural nerve and skin biopsies showed inflammation, myelin and axonal pathology. Extensive immunotherapy in one patient was followed by disease stabilization over 3 years. The other two patients died of rapid disease progression: one of them received no immunotherapy while the other had ineffective treatments with single administrations of intravenous immunoglobulin and rituximab. Our data suggest that septin multimer autoimmunity occurs in severe motor-predominant neuropathies which can clinically resemble a neurodegenerative LMND. Screening for septin multimer autoantibodies should be considered in patients presenting with this phenotype. Follow-up studies need to determine the direct pathogenicity of septin multimer autoantibodies, their potential as a biomarker of an autoimmune syndrome and responses to immunotherapy in larger cohorts.
ABSTRACT NUMBER: ESOC2026A250 MULTIMODALITY IMAGING FOR PATENT FORAMEN OVALE EVALUATION (MAINFRAME)
Knopp, Rachel, Flemming, Kelly, Scharf, Eugene, Keser, Zafer, Prink, Jessica, Johnson, Shari, Reeder, Guy, Brown, R D, Harmsen, William, Khan, Muhib, Flemming, Kelly D. , Scharf, Eugene , Keser, Zafer , Johnson, Shari, Reeder, Guy S.

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i135-i136

10.1093/esj/aakag023.225 Get It

Abstract Background and aims Patient foramen ovale (PFO) is a stroke risk factor evaluated using transthoracic echocardiogram (TTE), transesophageal echocardiogram (TEE), transcranial Doppler ultrasound (TCD), and cardiac computed tomography (CCT). TCD is non-invasive, but its diagnostic performance relative to other modalities is unclear. We hypothesized that TCD has high sensitivity but low specificity for PFO detection. Methods We conducted an IRB-approved, single-center retrospective study of patients undergoing TCD for right-to-left shunt (RLS) detection between January 2024 and April 2025. Patients were identified from the Neurosonology Laboratory Quality Database. Records were reviewed for demographics, comorbidities, and TTE, TEE, and CCT findings. Sensitivity, specificity, and positive and negative predictive values were calculated for TCD, TTE, and CCT relative to TEE, the gold standard. The sensitivity and specificity of TCD versus TTE were compared using McNemar test. Results Ninety-two patients were included. Mean age was 52.66 ± 15.78 years, and 51% were female; qualifying events included ischemic stroke or transient ischemic attack. RLS was detected in 53 patients (57.6%) by TCD, 17 (30%) by TTE, 18 (28.5%) by TEE, and 3 (21%) by CCT. TCD demonstrated 94% sensitivity and 53% specificity, (PPV 66%, NPV 89%). TTE showed 50% sensitivity and 82% specificity (PPV: 75%, NPV 61%), while CCT showed 33% sensitivity and 100% specificity (PPV 100%, NPV 33.3%). TCD had significantly higher sensitivity than TTE for RLS detection (p=0.039) with a non-significant difference in specificity (p=0.062), using TEE as the reference. Conclusions TCD has high sensitivity for RLS detection in patients with ischemic stroke or transient ischemic attack. Conflict of interest Rachel Knopp: nothing to disclose; Kelly Flemming: nothing to disclose; Eugene Scharf: nothing to disclose; Zafer Keser: nothing to disclose; Jessica Prink: nothing to disclose; Shari Johnson: nothing to disclose; Guy Reeder: nothing to disclose; Robert Brown: nothing to disclose; William Harmsen: nothing to disclose; Muhib Khan: nothing to disclose Table 1 - belongs to Results
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing
Muniz, Miguel, Orme, Jacob J. , Wei, Nancy , Koch, Regina M. , Scharf, Zachary, Gupta, Sounak , Kase, Adam M. , Pessoa, Rodrigo Rodrigues, Kwon, Eugene D., Andrews, Jack R. , Muniz, Miguel , Orme, Jacob J , Basourakos, Spyridon P. , Wei, Nancy , Scharf, Zachary , Gupta, Sounak , Kase, Adam M , Childs, Daniel S , Tsai, Jill , Bucheit, Leslie , Riaz, Irbaz Bin , Childs, Daniel S.

Mayo Clinic

Cancers | September 18, 2025 | Volume: 17 | Issue: 18 | Pages: 3048

10.3390/cancers17183048 | PMID 41008889 Get It

Background: Longitudinal genomic profiling through serial circulating tumor DNA (ctDNA) testing offers a noninvasive method to monitor clonal evolution in advanced prostate cancer. This study evaluated the frequency and nature of newly emergent and potentially actionable genomic alterations detected through serial testing in a real-world setting. Methods: We conducted a retrospective analysis of advanced prostate cancer patients who underwent multiple Guardant360 ctDNA tests between October 2020 and March 2023. The study focused on identifying new genomic alterations absent in the initial test, with particular attention to alterations relevant for on-label therapies, therapies approved in other oncologic indications (i.e., off-label), or a clinical trial. Results: Among 479 patients with at least two ctDNA tests, the median interval between the first and second evaluable tests was 207 days. New and potentially actionable alterations emerged in 57.8% of patients, including potential targets for on-label therapies (16.7%), off-label therapies (16.5%), and clinical trials (55.7%). Tumor mutational burden (TMB) increased from “low” to “high” in 11% of patients, although none had microsatellite instability or mismatch repair deficiency. In a Mayo Clinic subset, ten patients received olaparib based on treatment-emergent alterations, but none achieved a prostate-specific antigen (PSA) response. Two patients who transitioned from low to high TMB received pembrolizumab, both with progressive disease as best response. Conclusions: In a large real-world cohort, serial ctDNA testing frequently identified new alterations that were not detected at baseline and are potentially actionable therapeutic targets, highlighting the value of serial genomic profiling for capturing clonal dynamics. Additional research is needed to better establish a framework for retesting and to clarify how these results should influence subsequent treatment decisions.
Prolonged Water‐Only Fasting Followed by a Whole‐Plant‐Food Diet Promotes Fat‐Free Mass Recovery and Continued Fat Mass Loss in Adults With Overweight or Obesity
Gabriel, Sahmla , Ncube, Mackson, Goldman, David , Goldhamer, Alan , Myers, Toshia R. , Myers, Toshia R , Scharf, Eugene

Mayo Clinic

Obesity Science & Practice | August 5, 2025 | Volume: 11 | Issue: 4 | Pages: No page available

10.1002/osp4.70086 | PMID 40765844 Get It

ABSTRACTIntroductionConventional weight‐loss strategies often result in inadequate fat loss, poor sustainability, and unintended lean mass loss. Prolonged water‐only fasting followed by dietary change may offer an effective alternative, but its impact on body composition remains underexplored.MethodsThis secondary analysis utilized dual‐energy X‐ray absorptiometry (DXA) to assess changes in fat‐free mass (FFM), fat mass (FM), and bone mineral content (BMC) in adults [median (IQR) age: 62 (15) years with overweight or obesity. Participants underwent a median (IQR) of 14 (6) days of water‐only fasting, followed by 6 (3) days of food reintroduction with a whole‐plant‐food diet and a subsequent maintenance period of 45 (5) days. Study visits occurred at baseline and at the end of each period.ResultsAt end of fasting, FFM accounted for 74% of total BW lost during fasting. However, at the follow‐up visit, the median (IQR) percentage change in total BW, FFM, FM, and visceral adipose tissue (VAT) mass from baseline was −8.2 (5.2), −4.4 (5.6), −14.7 (8.9), −15.8 (12.8) %, respectively. At follow‐up, FM loss accounted for 67% of the total BW lost. BMC remained unchanged across all study visits.ConclusionsThis protocol produced sustained FM loss, specifically VAT mass, and FFM recovery, suggesting it may support effective weight management.
Neuropathy with Autoantibodies Against Septin Multimers in PNS Myelin Mimicking Lower Motor Neuron Disease (P4-11.028)
Miske, Ramona , Borowski, Kathrin , Ruprecht, Klemens , Mertins, Philipp , Sánchez-Sendin, Elisa , Wernick, Stephanie , Huemmert, Sophie, Komorowski, Lars , Scharf, Madeleine, Prüß, Harald , Arlt, Friederike A. , Appeltshauser, Luise , Dubey, Divyanshu , Stenzel, Werner , Radbruch, Helena , Meisel, Andreas , Endres, Matthias , Kirchner, Marieluise , Sánchez-Sendín, Elisa , Werner, Hauke , Doppler, Kathrin , McKeon, Andrew

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211012 Get It

Prolonged Water-Only Fasting Followed by a Whole-Plant-Food Diet Is a Potential Long-Term Management Strategy for Hypertension and Obesity
Zeiler, Evelyn , Gabriel, Sahmla , Ncube, Mackson, Thompson, Natasha , Newmire, Daniel E., Scharf, Eugene , Goldhamer, Alan , Myers, Toshia R. , Newmire, Daniel , Scharf, Eugene L , Goldhamer, Alan C , Myers, Toshia R

Mayo Clinic

Nutrients | November 20, 2024 | Volume: 16 | Issue: 22 | Pages: 3959

10.3390/nu16223959 | PMID 39599745 Get It

Objective: This single-arm, pre–post interventional trial (clinicaltrials.gov, NCT04515095) investigates the safety, feasibility, and potential effectiveness of prolonged water-only fasting followed by a whole-plant-food diet in the long-term management of hypertension and other cardiometabolic disorders. Methods: Safety was assessed based on adverse events (AEs) that were recorded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Feasibility was assessed based on retention rate, ability to complete minimal fast length, and intervention acceptability. Twenty-nine participants with stage 1 and 2 hypertension and without type 2 diabetes were enrolled from a residential fasting center. Results: Study retention was 100% at the end of the refeed and 93% at the six-week follow-up visit. Median (range) fasting and refeeding duration were 11 (7–40) and 5 (3–17) days, respectively, and 90% of participants were able to complete at least 7 days of fasting. The majority of AEs were mild (grade 1) and transient and there were no higher-grade or serious AEs. At the end of the intervention, median systolic/diastolic blood pressure had normalized to below 130/80 mmHg, body weight reduced by >5%, and anti-hypertensive medication was completely discontinued. These results were sustained for at least six weeks and potentially up to one year. Conclusions: Our data suggest that the intervention may be a feasible, well-tolerated, low-risk option for lowering and managing high blood pressure, excess body weight, and other cardiometabolic disorders in people with stage 1 and 2 hypertension.